AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8907343 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 17
Study 2181755 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbutaline 7.5 mg twice daily
Number of subjects: 17
Study 2181755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 395522 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 0
Study 395522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31838585 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 positivity assessment in gallbladder carcinoma
Number of subjects: 186
Study 31838585 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual HER2 inhibition treatment
Number of subjects: 186
Study 31838585 — intervention group
Group type: COMPARATOR
Intervention: HER2 status comparison between positive and negative groups
Number of subjects: 186
Study 31163062 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood induction (video clips followed by music excerpts with Velten statements)
Number of subjects: 551
Study 31163062 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood induction (video clips followed by music excerpts with Velten statements)
Number of subjects: 551
Study 31163062 — intervention group
Group type: COMPARATOR
Intervention: Velten statements (self-referential)
Number of subjects: 551
Study 31163062 — intervention group
Group type: COMPARATOR
Intervention: Closed eyes instructions
Number of subjects: 551
Study 31163062 — intervention group
Group type: COMPARATOR
Intervention: Neutral Velten statements (factual)
Number of subjects: 551
Study 27111441 — intervention group
Group type: EXPERIMENTAL
Intervention: PT+coaching (physiotherapy and coaching group)
Number of subjects: 168
Study 27111441 — intervention group
Group type: COMPARATOR
Intervention: PT-only (physiotherapy-only group)
Number of subjects: 168
Study 27111441 — intervention group
Group type: EXPERIMENTAL
Intervention: PT+coaching
Number of subjects: 168
Study 27111441 — intervention group
Group type: COMPARATOR
Intervention: PT-only
Number of subjects: 168
Study 28407999 — intervention group
Group type: EXPERIMENTAL
Intervention: Spacing strategy (TNF-blocker injection spacing)
Number of subjects: 98
Study 23376451 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg tid) plus Behavioral Weight Loss (BWL)
Number of subjects: 79
Study 23376451 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Behavioral Weight Loss (BWL)
Number of subjects: 79
Study 23376451 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat plus BWL
Number of subjects: 79
Study 23376451 — intervention group
Group type: EXPERIMENTAL
Intervention: BWL
Number of subjects: 79
Study 21454244 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel applied to the abdomen
Number of subjects: 36
Study 21454244 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel applied to the upper arms/shoulders
Number of subjects: 36
Study 21454244 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel alternating between abdomen and upper arms/shoulders
Number of subjects: 36
Study 19703642 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 7
Study 17726409 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose intramuscular dexamethasone (0.6 mg/kg, maximum 15 mg)
Number of subjects: 181
Study 17726409 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone (2 mg/kg, maximum 50 mg)
Number of subjects: 181
Study 17726409 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose intramuscular dexamethasone
Number of subjects: 181
Study 17726409 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone
Number of subjects: 181
Study 15210738 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy involved-field radiotherapy (RT)
Number of subjects: 172
Study 15210738 — intervention group
Group type: COMPARATOR
Intervention: Observation (OBS)
Number of subjects: 172
Study 15210738 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy involved-field RT
Number of subjects: 172
Study 15210738 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Gy RT
Number of subjects: 172
Study 11878525 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting for 20 minutes after administration of 3 ml of 0.5% hyperbaric bupivacaine solution
Number of subjects: 60
Study 11878525 — intervention group
Group type: COMPARATOR
Intervention: Sitting for 2, 5, or 10 minutes after administration of 3 ml of 0.5% hyperbaric bupivacaine solution
Number of subjects: 60
Study 11878525 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (2, 5, 10, and 20 minutes sitting)
Number of subjects: 60
Study 10450749 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF, 5 microg/kg/day from day 4 to day 8 of EMA chemotherapy
Number of subjects: 192
Study 10450749 — intervention group
Group type: COMPARATOR
Intervention: Placebo from day 4 to day 8 of EMA chemotherapy
Number of subjects: 192
Study 10450749 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 192
Study 10450749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 8696574 — intervention group
Group type: EXPERIMENTAL
Intervention: Durapore silk tape
Number of subjects: 2
Study 8696574 — intervention group
Group type: COMPARATOR
Intervention: Medipore soft cloth tape
Number of subjects: 2
Study 2618792 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting seconds (either mentally or aloud)
Number of subjects: 0
Study 2618792 — intervention group
Group type: COMPARATOR
Intervention: No counting of seconds
Number of subjects: 0
Study 2618792 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant force conditions
Number of subjects: 0
Study 2618792 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable force conditions ('Slow' and 'Rapid')
Number of subjects: 0
Study 2618792 — intervention group
Group type: EXPERIMENTAL
Intervention: Both counting and no counting groups
Number of subjects: 0
Study 793849 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 20
Study 793849 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 20
Study 31263283 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation of human fetal ventral mesencephalic tissue (hfVM)
Number of subjects: 11
Study 31263283 — intervention group
Group type: COMPARATOR
Intervention: Observational cohort assessments
Number of subjects: 11
Study 28068788 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic preparation (containing Lactobacillus helveticus and Bifidobacterium longum)
Number of subjects: 79
Study 28068788 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 79
Study 25555154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for 12 months
Number of subjects: 44
Study 25555154 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched by age and sex)
Number of subjects: 44
Study 23332688 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfibrillar collagen
Number of subjects: 0
Study 23332688 — intervention group
Group type: COMPARATOR
Intervention: Oxidized cellulose
Number of subjects: 0
Study 21132493 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptic condition
Number of subjects: 0
Study 21132493 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual condition
Number of subjects: 0
Study 21132493 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between haptic and visual deviations
Number of subjects: 0
Study 19474657 — intervention group
Group type: COMPARATOR
Intervention: LAC group: lansoprazole 30 mg twice daily, amoxicillin 1000 mg twice daily, and clarithromycin 500 mg twice daily for 14 days
Number of subjects: 464
Study 19474657 — intervention group
Group type: EXPERIMENTAL
Intervention: BLTM group: bismuth subcitrate 300 mg 4 times a day, lansoprazole 30 mg twice daily, tetracycline 500 mg 4 times a day, and metronidazole 500 mg twice daily for 10 days
Number of subjects: 464
Study 19474657 — intervention group
Group type: EXPERIMENTAL
Intervention: RBLTM group: ranitidine bismuth citrate 400 mg twice daily, lansoprazole 30 mg twice daily, tetracycline 500 mg 4 times a day, and metronidazole 500 mg twice daily for 10 days
Number of subjects: 464
Study 19474657 — intervention group
Group type: EXPERIMENTAL
Intervention: LTM group: lansoprazole 30 mg twice daily, tetracycline 500 mg 4 times a day, and metronidazole 500 mg twice daily for 10 days
Number of subjects: 464
Study 16499488 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin 'shots'
Number of subjects: 0
Study 16499488 — intervention group
Group type: COMPARATOR
Intervention: Alcohol beverage
Number of subjects: 0
Study 15571316 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg once daily for 14 days
Number of subjects: 67
Study 15571316 — intervention group
Group type: COMPARATOR
Intervention: Loratadine 10 mg once daily for 14 days
Number of subjects: 67
Study 11510874 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-induced dehydration after coffee consumption (caffeine 4.9 mg/kg, 3-4 cups)
Number of subjects: 10
Study 11510874 — intervention group
Group type: COMPARATOR
Intervention: Control (same amount of coffee, remained euhydrated)
Number of subjects: 10
Study 11510874 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-induced dehydration after coffee consumption
Number of subjects: 10
Study 9226080 — intervention group
Group type: EXPERIMENTAL
Intervention: Edinburgh Postnatal Depression Scale
Number of subjects: 200
Study 9226080 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Anxiety Depression Scale (depression subscale)
Number of subjects: 200
Study 9226080 — intervention group
Group type: EXPERIMENTAL
Intervention: Zung Self‐Rating Depression Scale
Number of subjects: 200
Study 9226080 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile of Mood States (depression subscale)
Number of subjects: 200
Study 9226080 — intervention group
Group type: EXPERIMENTAL
Intervention: Three instruments combined
Number of subjects: 200
Study 8543958 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 6595
Study 8543958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6595
Study 8543958 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised linkage reporting
Number of subjects: 6595
Study 8543958 — intervention group
Group type: COMPARATOR
Intervention: Traditional patient follow-up methods
Number of subjects: 6595
Study 2472488 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon-beta serine (IFN‐beta ser)
Number of subjects: 16
Study 2472488 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous interferon-beta serine (IFN‐beta ser)
Number of subjects: 16
Study 2472488 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of interferon-beta serine (180 X 10(6) IU)
Number of subjects: 16
Study 2472488 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose of interferon-beta serine (45 X 10(6) IU)
Number of subjects: 16
Study 30579569 — intervention group
Group type: EXPERIMENTAL
Intervention: BIKEN varicella-zoster vaccine (BVZV) with 23-valent polysaccharide pneumococcal vaccine (PPSV23)
Number of subjects: 52
Study 30579569 — intervention group
Group type: COMPARATOR
Intervention: 23-valent polysaccharide pneumococcal vaccine (PPSV23)
Number of subjects: 52
Study 28514964 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Elder Life Program (HELP)
Number of subjects: 0
Study 28514964 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 0
Study 26602296 — intervention group
Group type: EXPERIMENTAL
Intervention: WASH intervention (protecting babies from fecal ingestion)
Number of subjects: 0
Study 26602296 — intervention group
Group type: EXPERIMENTAL
Intervention: IYCF intervention (optimizing nutritional adequacy of infant diet)
Number of subjects: 0
Study 26602296 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined WASH and IYCF interventions
Number of subjects: 0
Study 26602296 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers of intestinal structure and function, microbial translocation, systemic inflammation, and hormonal determinants of growth and anemia
Number of subjects: 0
Study 24199742 — intervention group
Group type: COMPARATOR
Intervention: Physical exercise
Number of subjects: 98
Study 24199742 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 98
Study 24199742 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 98
Study 21823420 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Huoxue Recipe (BSHXR), one dose per day (taken in two times) for 8 weeks
Number of subjects: 45
Study 21823420 — intervention group
Group type: COMPARATOR
Intervention: Monopril 10 mg, once daily for 8 weeks (control group)
Number of subjects: 45
Study 21823420 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Huoxue Recipe (BSHXR)
Number of subjects: 45
Study 21823420 — intervention group
Group type: COMPARATOR
Intervention: Monopril 10 mg, once daily (control group)
Number of subjects: 45
Study 18465239 — intervention group
Group type: EXPERIMENTAL
Intervention: Renzapride (1, 2, or 4 mg/day)
Number of subjects: 168
Study 18465239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 16835029 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Response (RR) training
Number of subjects: 15
Study 16835029 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study 15018590 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (IVIg) therapy
Number of subjects: 100000
Study 15018590 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 100000
Study 15018590 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 100000
Study 11168085 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir therapy
Number of subjects: 14
Study 9049557 — intervention group
Group type: EXPERIMENTAL
Intervention: IVRA with prilocaine and clonidine 2 micrograms kg‐1
Number of subjects: 56
Study 9049557 — intervention group
Group type: COMPARATOR
Intervention: IVRA with prilocaine
Number of subjects: 56
Study 9049557 — intervention group
Group type: EXPERIMENTAL
Intervention: IVRA with prilocaine and systemic application of clonidine at tourniquet release
Number of subjects: 56
Study 8325047 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide 250 LRU (= 25 mg) capsules twice daily
Number of subjects: 476
Study 8325047 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide 50 mg enteric-coated tablets twice daily
Number of subjects: 476
Study 8325047 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide 100 mg enteric-coated tablets once daily
Number of subjects: 476
Study 8325047 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 476
Study 3630465 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest with additional daily administered glucose infusions
Number of subjects: 45
Study 3630465 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest with additional oral galactose applications
Number of subjects: 45
Study 3630465 — intervention group
Group type: COMPARATOR
Intervention: Strict bed rest alone
Number of subjects: 45
Study 30238060 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) counseling plus quarterly clinical examinations, fluoride varnish applications, toothbrush/toothpaste, and educational brochures
Number of subjects: 1065
Study 30238060 — intervention group
Group type: COMPARATOR
Intervention: Quarterly clinical examinations, fluoride varnish applications, toothbrush/toothpaste, and educational brochures
Number of subjects: 1065
Study 30238060 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) counseling plus intensive caries prevention activities
Number of subjects: 1065
Study 30238060 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1065
Study 27379995 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring (TM) group, 208 patients
Number of subjects: 299
Study 27379995 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group, 91 patients
Number of subjects: 299
Study 25174986 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based pedometer walking programme
Number of subjects: 42
Study 23801357 — intervention group
Group type: COMPARATOR
Intervention: Ponatinib 15 mg alone
Number of subjects: 22
Study 23801357 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib 15 mg with ketoconazole 400 mg daily for 5 days
Number of subjects: 22
Study 21166853 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin group (n=144, 70% of insulin users)
Number of subjects: 1047
Study 21166853 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin group (n=144)
Number of subjects: 1047
Study 21166853 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population (n=1047)
Number of subjects: 1047
Study 21166853 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population with cognitive impairment (n=235)
Number of subjects: 1047
Study 18305883 — intervention group
Group type: EXPERIMENTAL
Intervention: Processing speed at baseline
Number of subjects: 708
Study 18305883 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline neurocognitive performance
Number of subjects: 708
Study 18305883 — intervention group
Group type: EXPERIMENTAL
Intervention: Processing speed
Number of subjects: 708
Study 16567674 — intervention group
Group type: EXPERIMENTAL
Intervention: LifeSite hemodialysis access system
Number of subjects: 68
Study 16567674 — intervention group
Group type: COMPARATOR
Intervention: Tesio-Cath hemodialysis catheter
Number of subjects: 68
Study 12659614 — intervention group
Group type: EXPERIMENTAL
Intervention: Various potential treatments for FSD, specific interventions not detailed.
Number of subjects: 0
Study 10917987 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed saphenous vein
Number of subjects: 136
Study 10917987 — intervention group
Group type: COMPARATOR
Intervention: Polytetrafluoroethylene
Number of subjects: 136
Study 8725734 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 20
Study 8725734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1548516 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (40 to 1,000 mg/m2)
Number of subjects: 1028
Study 1548516 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC
Number of subjects: 1028
Study 6510389 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing 50 ppm carbon monoxide (CO)
Number of subjects: 10
Study 6510389 — intervention group
Group type: COMPARATOR
Intervention: Breathing purified air
Number of subjects: 10
Study 31544802 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional rehabilitation (NR) for 9±2 months with nutritional counselling and oral nutritional supplementation
Number of subjects: 102
Study 31544802 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional rehabilitation (NR) for 9±2 months with weight gain >7g/d
Number of subjects: 102
Study 31544802 — intervention group
Group type: COMPARATOR
Intervention: Nutritional rehabilitation (NR) for 9±2 months with weight gain <7g/d
Number of subjects: 102
Study 31544802 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (28 children who improved their BMI‐SDS after NR)
Number of subjects: 102
Study 31544802 — intervention group
Group type: COMPARATOR
Intervention: Group B (23 children who did not improve their BMI‐SDS after NR)
Number of subjects: 102
Study 31544802 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional rehabilitation (NR)
Number of subjects: 102
Study 28052451 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin infusion (loading dose of 35 IU/kg and continuous infusion of 10 IU/kg per hour for 6 hours)
Number of subjects: 12
Study 28052451 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin
Number of subjects: 12
Study 28052451 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 12
Study 26314877 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Competency Rating Scale (task-by-task approach)
Number of subjects: 83
Study 26314877 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Competency Rating Scale (functional domains approach)
Number of subjects: 83
Study 24840596 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment (PRT)
Number of subjects: 0
Study 24840596 — intervention group
Group type: COMPARATOR
Intervention: Structured Applied Behavior Analysis (ABA)
Number of subjects: 0
Study 22525397 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Organizers (AO)
Number of subjects: 65
Study 22525397 — intervention group
Group type: COMPARATOR
Intervention: Pretests (PT)
Number of subjects: 65
Study 20497139 — intervention group
Group type: EXPERIMENTAL
Intervention: PN 400 (enteric-coated naproxen 500 mg and immediate-release esomeprazole 20 mg)
Number of subjects: 864
Study 20497139 — intervention group
Group type: EXPERIMENTAL
Intervention: PN 400
Number of subjects: 864
Study 20497139 — intervention group
Group type: COMPARATOR
Intervention: EC naproxen
Number of subjects: 864
Study 17605967 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for symptomatic stenosis of more than 70%
Number of subjects: 0
Study 17605967 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for symptomatic stenosis of more than 50%
Number of subjects: 0
Study 17605967 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting for carotid stenosis
Number of subjects: 0
Study 17605967 — intervention group
Group type: COMPARATOR
Intervention: Endarterectomy vs stenting
Number of subjects: 0
Study 16117455 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (3 degrees C difference)
Number of subjects: 30
Study 16117455 — intervention group
Group type: COMPARATOR
Intervention: Group II (5 degrees C difference)
Number of subjects: 30
Study 16117455 — intervention group
Group type: COMPARATOR
Intervention: Group III (7 degrees C difference)
Number of subjects: 30
Study 12356214 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent mitoxantrone (MITO) therapy
Number of subjects: 1378
Study 12356214 — intervention group
Group type: COMPARATOR
Intervention: Published reports of nine additional studies of single-agent MITO therapy for MS
Number of subjects: 1378
Study 10028979 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmyocardial laser revascularisation (TMLR)
Number of subjects: 188